August 31, 2015November 5, 2015

Gilead Sciences Publishes Data From AMBITION Study of Treatment With Letairis and Tadalafil in Pulmonary Arterial Hypertension

Gilead Sciences, Inc., a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical needs, recently announced detailed data from its AMBITION randomized, double-blind, multicenter ... Read more

April 7, 2015November 5, 2015

Actavis Files ANDA for Generic Ambrisentan Tablets for PAH

News, Pulmonary Hypertension

Actavis recently confirmed that the company has filed an Abbreviated New Drug Application (ANDA) with the United States Food and Drug Administration (FDA) seeking approval to commercialize their formulation of Ambrisentan Tablets (5 and 10 mg). ... Read more